Analysts’ Weekly Ratings Updates for Pharmerica Corporation (PMC)

A number of firms have modified their ratings and price targets on shares of Pharmerica Corporation (NYSE: PMC) recently:

  • 8/9/2017 – Pharmerica Corporation was downgraded by analysts at Barrington Research from an “outperform” rating to an “underperform” rating.
  • 8/8/2017 – Pharmerica Corporation was downgraded by analysts at KeyCorp to an “overweight” rating.
  • 8/4/2017 – Pharmerica Corporation was downgraded by analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating. They now have a $19.20 price target on the stock, down previously from $28.95. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 8/3/2017 – Pharmerica Corporation was downgraded by analysts at Barrington Research from an “outperform” rating to an “underperform” rating.
  • 8/3/2017 – Pharmerica Corporation had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a $29.25 price target on the stock, up previously from $26.00.
  • 8/2/2017 – Pharmerica Corporation was downgraded by analysts at KeyCorp to an “overweight” rating.
  • 7/31/2017 – Pharmerica Corporation was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/18/2017 – Pharmerica Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation. As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues. “
  • 6/24/2017 – Pharmerica Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $28.00 price target on the stock. According to Zacks, “PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation. As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues. “
  • 6/23/2017 – Pharmerica Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation. As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues. “

Shares of Pharmerica Corporation (PMC) opened at 28.95 on Wednesday. Pharmerica Corporation has a 52-week low of $19.20 and a 52-week high of $29.00. The stock has a 50 day moving average of $26.08 and a 200 day moving average of $24.81. The company has a market cap of $910.19 million, a price-to-earnings ratio of 39.23 and a beta of 0.92.

Pharmerica Corporation (NYSE:PMC) last released its quarterly earnings data on Wednesday, August 2nd. The company reported $0.47 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.47. The firm had revenue of $592 million for the quarter, compared to analysts’ expectations of $592.96 million. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.47 earnings per share. On average, equities research analysts expect that Pharmerica Corporation will post $1.91 EPS for the current year.

What are top analysts saying about Pharmerica Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pharmerica Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit